Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 45Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Pleuropulmonary blastoma 1Patient Preference 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Inflammatory Breast Neoplasms 1HER2 Positive Breast Cancer 1Genomic Instability 1Cholangiocarcinoma 1Breast Cancer Metastatic 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × Ado-Trastuzumab Emtansine × Clear all
NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche

Phase 2 Completed
49 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡